Oxana Palesh1, Caroline Scheiber1, Shelli Kesler2, Richard Gevirtz3, Charles Heckler4, Joseph J Guido4, Michelle Janelsins4, Mallory G Cases1, Bingjie Tong1, Jessica M Miller5, Nick G Chrysson6, Karen Mustian7. 1. Department of Psychiatry and Behavioral Sciences. 2. Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center. 3. Alliant International University. 4. Department of Surgery, James P. Wilmot Cancer Institute, University of Rochester Medical Center. 5. Cancer Control Trials, Metro-Minnesota Community Oncology Research Consortium. 6. Hematology and Oncology, Novant Health Oncology Specialists. 7. James P. Wilmot Cancer Institute, Department of Surgery University of Rochester Medical Center.
Abstract
OBJECTIVE: Nearly 80% of cancer patients struggle with insomnia, which is associated with decreased heart rate variability (HRV) and quality of life (QOL). The aim of this secondary analysis was to evaluate the possible effects of Brief Behavioral Therapy for Cancer-Related Insomnia (BBT-CI), delivered during chemotherapy visits, on QOL and HRV in patients with breast cancer (BC). METHOD:QOL and HRV data were obtained during a pilot clinical trial assessing the feasibility and effects of BBT-CI on insomnia. A total of 71 BC patients (mean age = 52.5 years) were randomly assigned to either BBT-CI or a healthy-eating control intervention (HEAL). BBT-CI and HEAL were delivered over 6 weeks (2 face-to-face sessions plus 4 phone calls) by trained staff at 4 National Cancer Institute-funded Community Oncology Research Program clinics. QOL was measured with the Functional Assessment of Cancer Therapy (FACT-G) and HRV with the Firstbeat device at baseline and after intervention. RESULTS: There were significant improvements in QOL after intervention for BBT-CI (FACT-G, p = .009; FACT-B, p = .016; ANCOVA) and 5-min supine HRV measures (SDNN, p = .005; rMSSD, p = .004; HF, p = .009; ANCOVA) compared with HEAL. CONCLUSIONS: Patients randomized to BBT-CI showed improvements in QOL and HRV, providing support for BBT-CI's possible benefit when delivered in the community oncology setting by trained staff. A more definitive efficacy trial of BBT-CI is currently being planned with sufficient statistical power to evaluate the intervention's clinical utility. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
RCT Entities:
OBJECTIVE: Nearly 80% of cancerpatients struggle with insomnia, which is associated with decreased heart rate variability (HRV) and quality of life (QOL). The aim of this secondary analysis was to evaluate the possible effects of Brief Behavioral Therapy for Cancer-Related Insomnia (BBT-CI), delivered during chemotherapy visits, on QOL and HRV in patients with breast cancer (BC). METHOD: QOL and HRV data were obtained during a pilot clinical trial assessing the feasibility and effects of BBT-CI on insomnia. A total of 71 BCpatients (mean age = 52.5 years) were randomly assigned to either BBT-CI or a healthy-eating control intervention (HEAL). BBT-CI and HEAL were delivered over 6 weeks (2 face-to-face sessions plus 4 phone calls) by trained staff at 4 National Cancer Institute-funded Community Oncology Research Program clinics. QOL was measured with the Functional Assessment of Cancer Therapy (FACT-G) and HRV with the Firstbeat device at baseline and after intervention. RESULTS: There were significant improvements in QOL after intervention for BBT-CI (FACT-G, p = .009; FACT-B, p = .016; ANCOVA) and 5-min supine HRV measures (SDNN, p = .005; rMSSD, p = .004; HF, p = .009; ANCOVA) compared with HEAL. CONCLUSIONS:Patients randomized to BBT-CI showed improvements in QOL and HRV, providing support for BBT-CI's possible benefit when delivered in the community oncology setting by trained staff. A more definitive efficacy trial of BBT-CI is currently being planned with sufficient statistical power to evaluate the intervention's clinical utility. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Authors: Arnoldus J R Van Gestel; Malcolm Kohler; Jörg Steier; Sebastian Teschler; Erich W Russi; Helmut Teschler Journal: Respirology Date: 2011-08 Impact factor: 6.424
Authors: Sheila N Garland; Linda E Carlson; Alisa J Stephens; Michael C Antle; Charles Samuels; Tavis S Campbell Journal: J Clin Oncol Date: 2014-01-06 Impact factor: 44.544
Authors: Robert P Nolan; Markad V Kamath; John S Floras; Jill Stanley; Clement Pang; Peter Picton; Quincy R Young Journal: Am Heart J Date: 2005-06 Impact factor: 4.749
Authors: Oxana G Palesh; Joseph A Roscoe; Karen M Mustian; Thomas Roth; Josée Savard; Sonia Ancoli-Israel; Charles Heckler; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Ann M Berger; Brett R Kuhn; Lynne A Farr; James C Lynch; Sangeeta Agrawal; Julie Chamberlain; Susanna G Von Essen Journal: Psychooncology Date: 2009-06 Impact factor: 3.894
Authors: Oxana Palesh; Caroline Scheiber; Shelli Kesler; Michelle C Janelsins; Joseph J Guido; Charles Heckler; Mallory G Cases; Jessica Miller; Nick G Chrysson; Karen M Mustian Journal: Br J Cancer Date: 2018-07-20 Impact factor: 7.640
Authors: Yohannes W Woldeamanuel; Douglas W Blayney; Booil Jo; Sophie E Fisher; Catherine Benedict; Ingrid Oakley-Girvan; Shelli R Kesler; Oxana Palesh Journal: Cancer Date: 2021-08-06 Impact factor: 6.860